Related Experiment Videos
Prevention of stroke in patients with hypertension
1Department of Medicine, Sahlgrenska University Hospital/Ostra, Göteborg, Sweden. bjorn.dahlof@a-plusscience.com
Insights
Conventional hypertension treatment has limitations. Angiotensin II receptor blockers (ARBs), like telmisartan, may offer superior stroke protection beyond blood pressure reduction, a benefit to be explored in the PROFESS study.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Despite evidence for blood pressure lowering, conventional antihypertensive treatments do not fully mitigate major cardiovascular events in hypertensive patients.
- The choice of antihypertensive agent significantly impacts long-term cardiovascular outcomes, particularly stroke risk.
- Optimal blood pressure management requires 24-hour control, especially during early morning hours when stroke risk peaks.
Purpose of the Study:
- To investigate the potential of angiotensin II receptor blockers (ARBs) in providing stroke protection beyond blood pressure lowering.
- To evaluate the specific profile of the ARB telmisartan for stroke management.
- To explore the benefits of selective angiotensin II type 1 receptor blockade and 24-hour blood pressure control for stroke prevention.
Main Methods:
- The study will investigate the efficacy of ARBs, specifically telmisartan, in stroke prevention.
- Focus on 24-hour blood pressure control and blood pressure-independent effects on stroke risk.
- The Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) study will be central to the investigation.
Main Results:
- Angiotensin II receptor blockers (ARBs) demonstrate consistent benefits in stroke protection that exceed their blood pressure-lowering effects.
- Telmisartan exhibits a promising profile for stroke management due to its selective angiotensin II type 1 receptor blockade.
- Consistent 24-hour blood pressure control with telmisartan offers potential for enhanced stroke prevention.
Conclusions:
- Antihypertensive therapies with blood pressure-independent effects on stroke risk are crucial.
- ARBs, particularly telmisartan, represent a valuable therapeutic option for improving stroke prevention in hypertensive patients.
- Further investigation through the PROFESS study is warranted to confirm the stroke prevention potential of telmisartan.
Abstract:
Despite the substantial evidence of the benefits of lowering blood pressure, conventional treatment does not normalize the burden of major cardiovascular events in patients with hypertension. Data now suggest that the nature of the antihypertensive agent used may have an important impact on long-term cardiovascular outcomes, including stroke. Optimal treatment should provide powerful 24-hour blood pressure control, including during the early morning hours when the risk of stroke is highest. In addition, antihypertensive therapies selected should have positive blood pressure-independent effects on stroke risk. In contrast to angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers (ARBs) provide consistent benefits in stroke protection beyond blood pressure lowering. The ARB telmisartan has a particularly interesting profile for stroke management. Selective angiotensin II type 1 receptor blockade and 24-hour blood pressure control with telmisartan provide the potential for improved stroke prevention. This will be investigated in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) study.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Atherosclerosis IV: Nursing Management
Hypertension V: Nursing Management
Atherosclerosis III: Management
Hypertension III: Clinical Manifestations and Diagnostic Studies
Errors occurring during blood pressure monitoring
Several factors...